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a b s t r a c t
We have investigated whether reducing the overall size of adenovirus (Ad), through use of a vector
containing a shortened ﬁbre, leads to enhanced distribution and dissemination of the vector. Intravenous
or intraperitoneal injection of Ad5SlacZ (12 nm ﬁbre versus the normal Ad5 37 nm ﬁbre) or Ad5SpKlacZ
(shortened ﬁbre with polylysine motif in the H–I loop of ﬁbre knob domain) led to similar levels of lacZ
expression compared to Ad5LlacZ (native Ad5 ﬁbre) in the liver of treated animals, but did not enhance
extravasation into the tibialis anterior muscle. Direct injection of the short-ﬁbre vectors into the tibialis
anterior muscle did not result in enhanced spread of the vector through muscle tissue, and led to
only sporadic transgene expression in the spinal cord, suggesting that modifying the ﬁbre length or
redirecting viral infection to a more common cell surface receptor does not enhance motor neuron
uptake or retrograde transport.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Human adenovirus (Ad) is the most common platform for
delivery of therapeutic genes in gene therapy applications, and
has been used in approximately 23% of all human clinical trials to
date (Ginn et al., 2013). Ad has many advantages that have allowed
it to become so widely utilised. Deletion of the Ad early region 1
(E1) renders the vector replication defective and together with
additional deletion of the non-essential E3 region provides a
relatively large cloning capacity of 8 kb (Bett et al., 1993). Ad
vectors devoid of all viral protein sequences, termed helper-
dependent Ad (Palmer and Ng, 2005; Parks et al., 1996), further
increase this cloning limit to 36 kb (Parks and Graham, 1997). Ad
vectors remain predominantly episomal in transduced cells (Harui
et al., 1999; Hillgenberg et al., 2001; Jager and Ehrhardt, 2009;
Stephen et al., 2010; Wong et al., 2013), greatly reducing the risk
of insertional inactivation or activation of cellular genes. Ad has a
relatively good safety proﬁle (Amalﬁtano and Parks, 2002),
although at very high doses Ad can cause acute inﬂammation
and toxicity, which can be lethal (Brunetti-Pierri et al., 2004;
Morral et al., 2002; Raper et al., 2003). Upon systemic delivery in
most species, human Ad serotype 5 (the most commonly used
subtype) preferentially accumulates in the liver (Guo et al., 1996;
Nicol et al., 2004; Worgall et al., 1997). This preferential uptake
in the liver is due in part to the physical architecture of this tissue
(Ad becomes trapped in the liver sinusoids and fenestrations
(Bernt et al., 2003; Ross and Parks, 2003)), and the rapid scaven-
ging of Ad vectors by Kupffer cells in the liver triggers a robust
pro-inﬂammatory cytokine response (Lieber et al., 1997; Muruve
et al., 1999). A unique mechanism of Ad5 uptake in liver hepato-
cytes also contributes to Ad-induced inﬂammation. The Ad5 hexon
protein interacts with coagulation factor X which provides a
bridging interaction for binding to heparan sulphate proteoglycans
expressed on the surface of hepatocytes, allowing internalisation
(Alba et al., 2012; Bradshaw et al., 2010; Kalyuzhniy et al., 2008;
Waddington et al., 2008). Detection of internalised Ad-associated
factor X by toll-like receptor 4 in the endosome triggers an
innate immune response and inﬂammatory signalling (Doronin
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et al., 2012). However, Ad vectors containing mutations in the
hexon protein that prevent its interaction with factor X still
localise to the liver, although uptake by hepatocytes is dramati-
cally reduced (Alba et al., 2010; Kalyuzhniy et al., 2008). These
results suggest that physical constraints, other than receptor
binding, contribute signiﬁcantly to vector biodistribution.
The virion of Ad5 is a non-enveloped icosahedral capsid with a
diameter of 95 nm (for the main “body” of the virion, measured
vertex to vertex), and is composed of three major (II, III, and IV)
and ﬁve minor (IIIa, IVa2, VI, VIII, and IX) polypeptides (Berk,
2007; San Martin, 2012). Protein IV, more commonly known
as ﬁbre, forms trimers that project from the capsid surface at each
of the 12 vertices, and is the viral protein predominantly respon-
sible for interacting and binding to the cell surface through the
coxsackie–adenovirus receptor (CAR) (Bergelson et al., 1997, 1998).
For Ad5, the ﬁbre protein is 37 nm in length (Ruigrok et al., 1990;
van Raaij et al., 1999), thus increasing the overall size of the virus
to about 169 nm. Other human serotypes differ in the length of
ﬁbre and the cell surface proteins with which they interact, which
can signiﬁcantly inﬂuence the cell types that they preferentially
infect (Havenga et al., 2002). For example, the Ad35 ﬁbre protein is
only 13 nm in length (for an overall virion size of 110 nm), and
binds CD46 rather than CAR (Gaggar et al., 2003; Saban et al.,
2005). The ability of Ad to infect is intimately tied to its ability to
bind to the target cell. Cells with no or low levels of either the
primary or secondary Ad5 receptors are transduced at a greatly
reduced frequency (Goldman et al., 1996; Nalbantoglu et al., 1999).
CAR is frequently developmentally downregulated, thus reducing
Ad infection efﬁciency of mature tissues such as muscle and
neurons (Ahn et al., 2008; Nalbantoglu et al., 1999). Indeed,
numerous groups have improved Ad transduction of a variety of
cell types and tissues through introducing protein motifs into the
ﬁbre protein that redirect attachment to cell surface receptors
prevalent on most cells, such as a poly-lysine motif which allows
Ad to bind heparan sulphate proteoglycans (Bramson et al., 2004;
Wickham et al., 1997).
The preferential accumulation of Ad in the liver of treated
animals has meant that many of the gene therapy “successes”
when using Ad in animal models involve transduction of the
liver either to restore a functional deﬁciency to hepatocytes, or to
use this organ as a protein production factory to produce
large amounts of secreted protein (Brunetti-Pierri and Ng, 2011).
Use of Ad for therapy in other tissues has not been as successful.
For example, since Ad does not efﬁciently extravasate from
vasculature (Su et al., 2005), localised injections are required
for efﬁcient delivery to skeletal muscle (Quantin et al., 1992),
unlike adeno-associated virus-based vectors which can escape
circulation and transduce into all muscle groups after systemic
delivery (Gregorevic et al., 2004). Even after direct skeletal
muscle injection, Ad remains relatively localised and does not
disperse within the muscle (Meulenbroek et al., 2004; Quantin
et al., 1992). Thus, improvements in Ad vector design are necessary
to improve Ad utility for treating diseases of tissues other
than liver.
In this study, we asked whether decreasing the overall size of
the Ad vector, through substitution of the native Ad5 ﬁbre with
a chimeric ﬁbre containing the shorter shaft region from Ad9
(37 versus 12 nm ﬁbre, respectively) could enhance the ability of
Ad to extravasate from the vasculature into surrounding tissues,
or improve spread after direct injection in muscle. This reduction
in ﬁbre length results in a 30% decrease in the overall diameter of
the virus. We also address whether addition of a pK motif on
the knob domain of the shortened ﬁbre, to redirect infection to
more ubiquitous cell surface receptors, also enhanced vector
distribution, relative to vector containing the wildtype Ad5 ﬁbre
protein.
Results and discussion
Rationale and viral constructs
Ad-based vectors have a poor ability to extravasate into
surrounding tissue after systemic delivery and also a poor ability
to disperse beyond the site of injection after localised delivery in
most tissues. In part, the inability to spread is due to the relatively
large size of the Ad virion, which for Ad5 is approximately 169 nm.
For comparison, AAV6, which can effectively spread to all tissues
following systemic delivery (Gregorevic et al., 2004), is 25 nm in
diameter. We therefore investigated whether reducing the overall
size of the Ad vector, by decreasing the length of the ﬁbre protein,
could enhance its dispersion in mice. We generated an Ad vector
containing the short Ad9 shaft region of ﬁbre fused to the native
Ad5 ﬁbre knob domain (Shayakhmetov and Lieber, 2000), desig-
nated Ad5SlacZ, which decreased the overall size of the virus by
30% relative to a normal Ad5-based vector (Ad5LlacZ) (Fig. 1A).
Since the natural receptor for Ad, CAR, is downregulated on many
mature tissues, we also designed a derivative of Ad5SlacZ which
contained a poly-lysine motif in the HI loop of the knob domain,
Fig. 1. Adenovirus vectors used in this study. Panel A: wildtype Ad5 has a ﬁbre
length of 37 nm which, together with the main virion size of 95 nm, provide an
overall virion diameter of 169 nm. Substitution of the Ad5 shaft region for that of
Ad9 reduces the length of ﬁbre to 12 nm, and reduces the overall virion diameter
to 119 nm, or 30% smaller than Ad5. Viruses are drawn to approximate scale. Panel
B: all viruses are deleted of the Ad early region 1 (E1) and E3, and encode the E. coli
lacZ gene under the regulation of the human cytomegalovirus (CMV) immediate
early enhancer/promoter and bovine growth hormone polyadenylation sequence
(pA). Ad5SpKlacZ also contains a polylysine motif within the HI loop of the knob
domain of ﬁbre. Panels C and D: virus particles (109) were lysed in SDS–protein
loading buffer, separated by SDS–PAGE, and the amount of hexon (Panel C) and
ﬁbre (Panel D) was determined by immunoblot.
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designated Ad5SpKlacZ. Attachment for this virus occurs through
binding to heparan sulphate proteoglycans which are present on
the surface of most cells. Ad5SpKlacZ is not ablated for binding to
CAR. All of these viruses are deleted of the Ad E1 and E3 regions,
and encode the Escherichia coli lacZ gene under regulation by the
human cytomegalovirus immediate early enhancer/promoter and
bovine growth hormone polyadenylation sequence (Fig. 1B). These
viruses were tested in tissue culture and mice for enhanced uptake
and dispersion to a number of speciﬁc tissues.
All three viruses grew well and gave a similar yield upon large
scale virus puriﬁcation (data not shown). Since the viruses may
have different inherent ability to infect cells, including the 293 cell
lines typically used for virus titering, we quantiﬁed the amount of
virus by particle count and veriﬁed the accuracy of the particle
counts by analysing the same number of particles of each virus by
immunoblot. Similar signal intensity was obtained for each virus
(Fig. 1C). We also veriﬁed the size of the ﬁbre protein for each of
these viruses (Fig. 1D).
Infection of cell lines in vitro
We next compared the ability of the viruses to infect several
different common cell lines derived from speciﬁc tissues: A549
(human lung adenocarcinoma), MN1 (rat motor neuron-like), and
undifferentiated or differentiated C2C12 (mouse myoblasts). Cells
grown in 35 mm dishes were infected in triplicate with an MOI of
10, and cell lysates were assayed 24 h postinfection for β-gal
activity using a chemiluminescence assay. All viruses infected
A549 cells with very high efﬁciency, and gave rise to β-gal activity
signiﬁcantly above background (Fig. 2A), which is perhaps not
surprising given the high-level of expression of CAR on these cells
(Hidaka et al., 1999). Substituting the long ﬁbre shaft of Ad5 for the
short shaft of Ad9 reduced the infection efﬁciency of A549 cells by
about 10-fold, but addition of the pK motif to the short-ﬁbre virus
restored the infection level, as gauged by β-gal activity, to that of
native Ad5 ﬁbre.
In the motor neuron-like MN1 cells, expression from all viruses
was equal and approximately 10-fold higher than background,
but the overall level of β-gal activity was approximately 10- to
100-fold lower than that observed in A549 cells (Fig. 2B). This
latter observation is consistent with the apparent developmental
down-regulation of CAR expression in spinal cord of mice (Hotta
et al., 2003) and with our previous data showing that Ad5 does not
infect MN1 cells well (Goulet et al., 2013b). Addition of the pK
motif on the Ad5S knob did not enhance infection of MN1 cells.
Similar to A549 cells, viruses infected both undifferentiated and
differentiated C2C12 cells with very high efﬁciency, and cells
treated with the vector containing the native Ad ﬁbre showed an
approximately 10 fold higher level of β-gal activity than the other
viruses (Fig. 2C and D).
Virus infection in vivo
To examine whether reducing the length of ﬁbre protein, and
thus the overall size of the virus, enhanced extravasation into
surrounding tissue, we evaluated β-galactosidase expression in
liver (a site for high level uptake of virus, regardless of injection
route) and in TA muscle by chemiluminescence activity assay
(Fig. 3). We used three doses of virus: 51011 VP/kg (low),
11012 VP/kg (middle) and 51012 VP/kg (high), and either IP
Fig. 2. Analysis of transgene expression from Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in tissue culture. A549 (Panel A), MN1 (Panel B) or undifferentiated (Panel C) or
differentiated (Panel D) C2C12 cells in 35 mm dishes were infected at a multiplicity of infection (MOI) of 10 with Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ and, 24 h later, crude
protein extracts were prepared and assayed for β-gal activity using a commercial chemiluminescent assay. Data is shown as average and standard deviation of the mean
(n¼3), n¼po0.05.
E.R. McFall et al. / Virology 468-470 (2014) 444–453446
or IV injection. As a control, we injected the TA muscle directly
with the highest dose of the three viruses. The data shows that the
viruses were capable of infecting muscle and gave rise to very high
levels of β-galactosidase activity (Fig. 3A). Of note, when normal-
ised to the amount of protein in the sample, after direct TA muscle
injection, approximately 20% of the β-gal activity was detected in
the liver (Fig. 3B), suggesting there is signiﬁcant escape from the
site of injection to the liver. IP injection of the three viruses led to
only a modest increase in β-gal activity in the TA muscle at the
highest virus dose (Fig. 3C), and a dose dependent increase in
expression in the liver for Ad5SlacZ and Ad5LlacZ (Fig. 3D).
Interestingly, after IP injection, no liver expression was observed
for Ad5SpKlacZ, regardless of dose, suggesting that the virus may
efﬁciently and preferentially infect the peritoneum and is not
available for infection elsewhere. IV injection of the viruses did not
result in a signiﬁcant increase in β-gal activity in the TA muscle,
with the exception of the highest dose of Ad5LlacZ (Fig. 3E). For all
viruses, following IV injection there was a signiﬁcant dose-
dependent increase in β-gal activity in the liver of treated animals,
with an approximately equal level of expression for all viruses
(Fig. 3F).
We also examined β-gal expression by histochemistry in tissue
sections of TA muscle after TA, IP or IV injection of the viruses
(Fig. 4). Mice were injected with the highest dose of virus
(51012 VP/kg), the tissue was isolated 24 h later, ﬁxed, sectioned
and stained for β-gal activity. For the TA muscle, representative
images from the top, middle and bottom of the muscle are
shown. Consistent with our chemiluminesence activity assays,
we observed signiﬁcant levels of β-gal activity after direct injec-
tion of the three viruses into the TA muscle, but very limited
expression after IP or IV injection (Fig. 4). Thus, systemic delivery
of either Ad vector containing wildtype ﬁbre or a shortened ﬁbre
does not lead to enhanced transduction of muscle.
Dispersion of virus after TA muscle injection
We next examined whether a decrease in virus size resulted
in improved dispersion throughout the muscle following TA
Fig. 3. Analysis of transgene expression from Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in TA muscle and liver after in vivo vector administration. Mice (n¼2–3 per treatment)
were injected with a low (51011 VP/kg), middle (11012 VP/kg) or high (51012 VP/kg) dose of Ad5LlacZ, Ad5SlacZ, Ad5SpKlacZ, or PBS by direct TA injection (Panels A
and B) or systemically by intraperitoneal (IP, Panels C and D), or intravenous (IV, Panels E and F) injection. 24 h post-injection, the TA muscle and liver were removed,
processed, and assayed for β-gal activity (normalised to μg of protein in the sample). Average and standard deviation of the mean are shown, n¼po0.05.
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injection. To examine the kinetics of expression, mice were
injected in the TA muscle with our highest dose of vector
(51012 VP/kg), and expression analysed in muscle and liver at
1, 2 and 3 days post-injection. In the TA muscle, all viruses
produced a level of β-gal activity approximately 100-fold above
background, and expression was relatively stable over the 3-day
time course (Fig. 5A). In contrast, β-gal activity in the liver was
highest at day 1, and steadily declined by about 1 log over the next
2 days, with all three viruses showing a similar trend (Fig. 5B). This
latter observation is consistent with previous studies that have
shown a robust anti-Ad inﬂammatory response in liver, in part due
to uptake and activation of liver Kupffer cells, leading to a dramatic
reduction in viral genomes within the ﬁrst 24 hpi, and a more
gradual decline over the next several days (Lieber et al., 1997;
Wolff et al., 1997; Worgall et al., 1997). Histochemical analysis of
TA muscle sections from treated mice showed that all viruses
resulted in a signiﬁcant level of β-gal activity (Fig. 5C), with no
signiﬁcant difference in the per cent of the cross sectional area
transduced by each virus (Table 1). These results suggest that
reducing the size of the virus, through reduced ﬁbre length, does
not signiﬁcantly alter dispersion of the virus in muscle after
localised delivery.
Retrograde transport of Ad to the spinal cord after TA muscle injection
is inefﬁcient
Studies in rats have shown that injection of muscle with Ad can
lead to efﬁcient retrograde transport of the virus to motor neuron cell
bodies in the spinal cord (Baumgartner and Shine, 1998; Ghadge et al.,
1995; Nakajima et al., 2008). Retrograde transport has also been
observed for a number of different viral vectors including adeno-
associated virus (Bockstael et al., 2011) and lentivirus (Hirano et al.,
2013). To determine if our modiﬁed viruses demonstrated altered
retrograde transport, we injected TAmuscle with 51012 VP/kg of the
various viruses in a solution containing Texas-Red conjugated Dextran.
Dextran is taken up bymotor neurons, which would ﬂuoresce red, and
allows us to identify the appropriate region of the spinal cord for β-gal
staining (Nance and Burns, 1990). Spinal cords from treated mice were
sectioned until ﬂuorescent motor neurons were visible (Fig. 6A), and
the next adjacent section was stained with X-gal to visualise the
efﬁciency of Ad transduction. As shown in Fig. 6B, we only observed
sparse and sporadic expression of β-gal in motor neurons, regardless
of virus identity. These results suggest that the efﬁciency of uptake and
retrograde transport of Ad in mice is low, and is not improved by
reduced ﬁbre size or the presence of a heparan sulphate proteoglycan
binding region on the ﬁbre knob. Given that Ad does not infect motor
neuron-like cells in culture very efﬁciently (Fig. 2B), it is perhaps not
surprising that the efﬁciency of uptake and transduction of motor
neurons in vivo is low. An enhancement in motor neuron uptake may
be achieved through introduction of peptide motifs into the Ad capsid
that speciﬁcally target infection to neurons (Poulin et al., 2011;
Terashima et al., 2009), but this has yet to be examined. Alternatively,
canine adenovirus has shown an enhanced ability to infect neurons
and undergo retrograde transport (Soudais et al., 2001), suggesting it
may be more amenable for the treatment of diseases of the motor
neuron such as spinal muscular atrophy or amyotrophic lateral
sclerosis (Goulet et al., 2013a; San Sebastian et al., 2013).
In this study, we have examined whether reducing the size of
the adenovirus vector, through reduction in the length of the ﬁbre
protein, could result in enhanced delivery and distribution to
muscle after systemic delivery. In general, reduction in the size
of the ﬁbre protein, with or without a polylysine motif to redirect
virus binding to cell surface heparan sulphate proteoglycans, had
little effect on enhancing muscle cell transduction following
systemic or localised delivery. Previous studies have suggested
that the Ad2 ﬁbre protein, which is very similar to the Ad5 ﬁbre
protein, may naturally bend, which would effectively reduce the
overall diameter of Ad5LlacZ to closer to that of Ad5SlacZ. The Ad2
(and Ad5) ﬁbre protein shaft region contains 22 β-repeats. The
twenty-ﬁrst repeat, located just before the knob domain, is a non-
consensus repeat that may allow for a small degree of bending
between knob and shaft (van Raaij et al., 1999). More importantly,
the third β-repeat is also non-consensus, and may provide
signiﬁcant ﬂexibility to the ﬁbre protein. In cryo-EM images, Ad2
ﬁbre appears “kinked” in this approximate region (Chiu et al.,
2001; Stewart et al., 1997). Replacing these ﬂexible repeats with
the corresponding regions of the more rigid ﬁbre from Ad37
abolished infection suggesting that bending of ﬁbre does occur
naturally and is important for Ad5 infection (Wu et al., 2003).
Molecular modelling showed that the ﬁbre protein would need to
bend at an angle of at least 701 to allow proper alignment of
the RGD motif contained in penton protein with surface exposed
integrins (Wu et al., 2003). If ﬁbre is capable of folding back
Fig. 4. Histological analysis of β-gal expression in the TA muscle of treated animals.
Mice were treated with 51012 VP/kg of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ by
direct TA injection or systemically by intraperitoneal (IP) or intravenous (IV)
injection. The TA muscle was removed 24 h post-treatment, ﬁxed, sectioned and
stained for β-gal activity. Sections were viewed using an AxioCam Axiophot2 light
microscope at 10 magniﬁcation.
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towards the body of the Ad virion at such an acute angle, it would
reduce the distance that the Ad5 ﬁbre protrudes from the main
body of the Ad virion from 37 nm to only 16 nm. Short ﬁbre
shaft proteins, such as that of Ad9 used in this study, are predicted
to be rigid (Chiu et al., 2001). Thus, the effective difference in
length of the short and long ﬁbre proteins used in this study may
not be dramatically different, which could contribute to the similar
transduction proﬁles observed for these viruses.
Another factor that could contribute to the similar transduction
efﬁciencies of Ad5SlacZ and Ad5LlacZ may be the impact of the
negative charge conferred on the virion by the Ad5 hexon protein. As
discussed by Shayakhmetov and Lieber (2000), the surface exposed
hypervariable regions of hexon from Ad serotypes with naturally short
ﬁbre proteins tend to be neutral or positively charged (Crawford-
Miksza and Schnurr, 1996), allowing for the relatively close apposition
of the Ad virion and negatively-charged cell membrane. In contrast,
the hypervariable regions on the Ad5 hexon have a strong negative
charge that may act as a signiﬁcant repulsive force when combined
with the short ﬁbre protein, compromising efﬁcient interaction of
virus with the cell (Shayakhmetov and Lieber, 2000).
As others have also shown (Guo et al., 1996; Worgall et al., 1997),
we observed that regardless of the route of administration, Ad
naturally preferentially accumulates in the liver, leading to high level
gene expression in this tissue. Many of the successes in preclinical
studies using Ad-mediated gene transfer involve diseases of the liver
or use the liver as a protein-production factory for secreted protein
(Brunetti-Pierri and Ng, 2011). Ad vectors have a natural tropism for
liver and can persist and express a transgene for greater than 7 years
after a single IV injection in non-human primates (Brunetti-Pierri
et al., 2013). However, as demonstrated in this study, use of Ad
vectors to target gene expression to alternative tissues remains a
challenging aspect of Ad vector development.
Materials and methods
Cell culture
All cell culture media and reagents were obtained from
Invitrogen (Burlington, ON). 293 (Graham et al., 1977), 293N3S
(Graham, 1987) and A549 (American Type Culture Collection) cells
were grown in monolayer in minimum essential medium (MEM)
supplemented with 2 mM Glutamax, 0.1 mg/ml streptomycin and
100 U/ml penicillin, and 10% foetal bovine serum (FBS). MN1 cells
Fig. 5. Kinetics and area of transgene expression in the TA muscle of treated mice. Mice were injected in the TA muscle with 51012 VP/kg of Ad5LlacZ, Ad5SlacZ and
Ad5SpKlacZ, and the TA muscle and liver was removed at 1, 2 or 3 days post-injection. Muscle (Panel A) and liver (Panel B) were processed and analysed for β-gal activity by
chemiluminescence assay. Shown is the average and standard deviation (n¼2–3), n¼po0.05. Panel C: TA muscles were processed for histology to examine β-gal expression.
Table 1
Areaa of TA muscle expressing β-gal following TA injection.
Ad5LlacZ Ad5SlacZ Ad5SpKlacZ
Top Middle Bottom Top Middle Bottom Top Middle Bottom
24 h 25.176.5 25.574.2 35.9723.5 18.4710.7 20.470.8 14.175.1 20.671.6 16.771.4 21.3722.6
48 h 27.0713.4 25.0714.6 22.1711.8 42.171.2 43.173.6 21.9711.7 31.6712.5 28.2715.5 21.7721.7
72 h 20.0716.9 17.3710.6 13.379.1 26.175.1 21.8718.2 9.778.6 30.973.4 26.7718.1 9.977.7
a Images from stained sections were analysed using Image J. A colour intensity threshold was applied to determine the area of the muscle section showing X-gal staining,
which is reported as the percentage of the total cross-sectional area of the muscle.
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(Salazar-Grueso et al., 1991) were maintained in Dulbecco's mod-
iﬁed Eagle's medium (DMEM, Sigma-Aldrich) supplemented with
10% FBS, 2 mM L-Glutamax, 0.1 mg/ml streptomycin and 100 U/ml
penicillin, and were a kind gift of Dr. Jocelyn Cote (University of
Ottawa). C2C12 cells (Blau et al., 1985) were grown in DMEM
supplemented with 10% FBS, 2 mM L-glutamine, 0.1 mg/ml strep-
tomycin and 100 U/ml penicillin, and conﬂuent plates were
switched to medium supplemented with 2% horse serum to induce
differentiation. C2C12 cells were allowed to differentiate for 4 days
before infection.
Generation and propagation of viruses
All of the viruses used in this study are deleted of the Ad5 early
region 1 (E1) and E3 regions, and were generated and propagated
using standard techniques (Ross and Parks, 2009). A plasmid
containing an Ad5 genome encoding a modiﬁed ﬁbre protein with
the Ad9 shaft and Ad5 knob was obtained from Drs. Dmitry
Shayakhmetov and Andre Lieber (University of Washington)
(Shayakhmetov and Lieber, 2000). The modiﬁed ﬁbre gene was
subcloned into an E1/E3-deleted Ad genomic plasmid, pRP2014
(Christou and Parks, 2011; Poulin et al., 2010), and a cytomegalo-
virus immediate early enhancer/promoter-lacZ expression cassette
(pCA38, (Addison et al., 1997)) was introduced to replace the
E1-deletion, using RecA-mediated recombination (Chartier et al.,
1996), as detailed previously (Willemsen, 2009), and designated
Ad5SlacZ. To introduce the poly-lysine motif into the H–I loop of
the knob domain of the short ﬁbre, a BglII/PstI fragment contain-
ing part of the knob domain was ﬁrst subcloned into pSP72
(Promega). This plasmid was PCR ampliﬁed with the synthetic
oligonucleotides 50 ata gcc ggc aaa aag aaa aag aaa aag aaa gga gca
cca agt gca tac tct atg tca ttt tca tg 30 and 50 taa gcc ggc agt tgt gtc
tcc tgt ttc ctg tgt acc g 30, which prime in opposite directions
around the plasmid, creating a linear molecule with compatible
NgoMIV ends. Recircularization of the plasmid creates a molecule
encoding a short ﬁbre knob domain that has been changed from
amino acids GDTT-PSAY to GDTT-AGKKKKKKKGA-PSAY. The mod-
iﬁed ﬁbre protein was recombined into pRP2014 to replace the
native Ad5 ﬁbre, and the CMV-lacZ expression cassette added to
replace the E1-deletion, and designated Ad5SpKlacZ. Recombina-
tion of pCA38 and pRP2014 generated the control virus Ad5LlacZ.
Particle counts were used to determine the titre of the vector; an
aliquot of virus was diluted in assay buffer (1 mM EDTA, 0.1 SDS),
heated for 20 min at 65 1C, and the absorbance determined as 1
A260¼1.11012 particles.
Immunoblot analysis
To examine the level of incorporation of the modiﬁed ﬁbre
proteins, we assayed dilutions of the virus stock for hexon (loading
control) and ﬁbre signal by immunoblot. Viruses were diluted to
109 viral particles in a total of 10 μl of PBS, and combined with
equal volume of 2 SDS/PAGE protein loading buffer (62.5 mM
Tris HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue,
5% β-mercaptoethanol). Samples were boiled for 5 min, and
separated by electrophoresis on a 12% SDS–polyacrylamide gel.
The separated proteins were transferred to a polyvinylidene
diﬂuoride membrane (Immobilon-P, Millipore) and the membrane
was probed with an antibody raised against all Ad capsid proteins
(ab6982, 1/10,000; Abcam) or ﬁbre (MS-1027-P0, 1/1000, NeoMar-
kers). Binding of the primary antibody was detected using a goat
or mouse anti-rabbit secondary antibody conjugated to
Fig. 6. Inefﬁcient retrograde transport of Ad vectors in motor neurons after TA muscle injection in mice. Mice were injected in the TA muscle with 51012 VP/kg of Ad5LlacZ,
Ad5SlacZ and Ad5SpKlacZ in a solution containing 16 mg/ml Texas Red-conjugated Dextran. Spinal cords were removed 48 h post-injection, ﬁxed, and longitudinal sections
were collected until motor neurons were detected by immunoﬂuorescence. The next sequential section was then stained for β-gal activity, and viewed using a Leica M80
microscope.
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horseradish peroxidase (BioRad) and visualised by chemilumines-
cence reaction (Thermo Scientiﬁc ECL western blotting substrate)
and autoradiography.
Infection assays in vitro
Triplicate 35 mm dishes of A549, MN1, or undifferentiated or
differentiated C2C12 were seeded at a density of 0.3106 cells per
dish. The next day cells were infected at an multiplicity of infection
(MOI) of 10 with Ad5LlacZ, Ad5SlacZ or Ad5SpKlacZ (or mock
infected), except for one series of C2C12 cells, which was switched
to differentiation medium (DMEMþ2%HS), and infected after
4 days of differentiation. Crude protein extracts were prepared
from the infected cells 24 h later by lysing the cells with 175 μl of
Lysis Solution (Applied Biosystems). The samples were centrifuged
at 9400g for 2 min at room temperature (RT) and the supernatant
collected and stored at 80 1C. The samples were thawed and
assayed for β-galactosidase (β-gal) activity using a commercial
chemiluminescence assay (Galacto-star, Applied Biosystems) and a
20/20n luminometer (Turner BioSystems).
In vivo injections and tissue harvest
All animal experiments were approved by and performed
according to the guidelines set by the Animal Research Ethics
Board at the University of Ottawa (Ottawa, ON, Canada). Six to
eight week-old C57Bl/6J mice (Charles River) were injected intra-
venously (IV) through the tail vein or intraperitoneally (IP) with
100 μl virus or PBS, or anaesthetised with halothane, and injected
with virus or PBS in a volume of 25–30 μl in both the right and
left tibialis anterior (TA) muscles. Three viral concentrations
were used: 51011 VP/kg (low), 11012 VP/kg (middle) and 5
1012 VP/kg (high). One, two or three days later (as indicated in the
speciﬁc experiment described below), the mice were euthanized
with 100 μl euthanyl (CDMV Inc., Quebec City, QC). For determin-
ing the level of β-gal activity, liver and TA muscles from treated
animals were removed and immediately frozen in liquid nitrogen
and stored at 80 1C until processed as described below. For
immunohistochemistry, TA muscles and the spinal cord were
removed and immediately incubated in 2% paraformaldehyde
(PFA) for 1 h, washed 3 times with PBS, and then incubated in
30% sucrose in PBS for 24–72 h. Tissues were equilibrated in 50:50
30% sucrose/OCT (Tissue-Tek 4583, VWR) for 1–2 h on a rocking
platform. Samples were embedded in the same 50:50 mixture
by ﬂash freezing in liquid nitrogen and stored at 80 1C until
sectioning. The tissues were sectioned using a cryostat in trans-
verse or longitudinal 12 mm sections, mounted on a glass slide, and
stored at 20 1C.
β-galactosidase staining
Tissue sections were hydrated in PBS for 1–2 min then fully
submerged in X-gal stain (5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6,
2 mM MgCl2, 1 mg/ml 5-bromo-4-chloro-3-indolyl-β-d-galacto-
pyranoside in PBS) for 24 h at 37 1C. Slides were washed in PBS
for 1 min and covered with a glass cover slip in a 1:1 mixture of
PBS and 30% glycerol. Quantiﬁcation of the stained areas was
performed using Image J (Wayne Rasband, Research Services
Branch, National Institute of Mental Health, Bethesda, Maryland,
USA). A colour intensity threshold was applied to determine
the area of the muscle section showing X-gal staining, which is
reported as the percentage of the total cross-sectional area of the
muscle.
To examine the efﬁciency of retrograde transport to motor
neurons after TA injection, mice were injected with 51012 VP/kg
of Ad5LlacZ, Ad5SlacZ and Ad5SpKlacZ in a solution containing
16 mg/ml Texas Red-conjugated 3000 MW Dextran. The Texas-
Red-conjugated Dextran is taken up by the motor neuron termini,
and undergoes retrograde transport to mark the motor neuron cell
body (Nance and Burns, 1990). Spinal cords were removed 48 h
post-injection. Tissues were ﬁxed as described above and long-
itudinal sections were collected until Texas Red stained-motor
neurons were detected by immunoﬂuorescence. The next sequen-
tial section was then stained for β-gal activity and viewed using a
Leica M80 microscope.
Chemiluminescent β-galactosidase assay
The liver samples were processed as previously described
(Parks et al., 1999). Brieﬂy, the entire liver was homogenised in
1 ml of PBS using a Power Gen 125 (Fisher Scientiﬁc) at a speed of
5.5 for approximately 10 s. The samples were sonicated twice for
15 s on ice, with a 10 s rest period in between. Samples were
centrifuged at 375g for 5 min and the supernatant removed to a
fresh tube. TA muscles where pulverised using a liquid nitrogen
chilled-mortar and pestle. The ground muscle was transferred to a
microfuge tube, and solubilized in 400 μl RIPA buffer (50 mM Tris
pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% glycerol, 1% NP40, and
protease inhibitors). Both liver and TA muscle samples were
heated in a 55 1C water bath for 15 min (to inactivate endogenous
β-gal activity), followed by a ﬁnal centrifugation at 16000g for
10 min. The supernatants were collected and assayed for β-gal
activity using a commercial kit (Galacto-star, Applied Biosystems)
and a 20/20n luminometer (Turner BioSystems). Data was normal-
ised to the amount of protein in each sample, as determined by
Bradford assay (BioRad).
Statistical analysis
SigmaStat 2.0 was used to determine statistical signiﬁcance. All
error bars represent standard deviation and the p-Value was set
to 0.05.
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